Table 2

Treatment-related adverse events (AEs)

Grade 1–2Grade 3Grade 4Grade 5
Any treatment-related AE58 (96.7%)34 (56.7%)4 (6.7%)1 (1.7%)
Leukocytopenia22 (36.7%)26 (43.3%)4 (6.7%)0
Thrombocytopenia31 (51.7%)4 (6.7%)00
Anemia47 (78.3%)3 (5.0%)1 (1.7%)0
Increased AST/ALT23 (38.3%)2 (3.3%)00
Increased γ-GT9 (15.0%)000
Increased LDH/AKP37 (61.7%)000
Nausea10 (16.7%)000
Vomiting5 (8.3%)000
Diarrhea4 (6.7%)000
Constipation6 (10.0%)000
Asthenia or fatigue18 (30.0%)000
Fever6 (10.0%)2 (3.3%)00
Alopecia42 (70.0%)000
Blurred vision3 (5.0%)1 (1.7%)00
Neurotoxicity3 (5.0%)000
Proteinuria5 (8.3%)000
Urinary infection2 (3.3%)000
Cutaneous capillary proliferation16 (26.7%)000
Rash maculopapular10 (16.7%)000
Pruritus10 (16.7%)000
Pneumonia1 (1.7%)2 (3.3%)01 (1.7%)
Hypothyroidism4 (6.7%)000
Hyperthyroidism1 (1.7%)000
  • AKP, alkline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GT, glutamyltranspeptidase; LDH, lactate dehydrogenase.